Skip to Content
Merck

Key Documents

View All Documentation

SML0956

Dexmedetomidine hydrochloride

≥98% (HPLC), α2-adrenergic agonist , powder

Synonym(s):

(+)-Medetomidine hydrochloride, (S)-Medetomidine hydrochloride, 4-[(S)-α,2,3-Trimethylbenzyl]imidazole monohydrochloride, 5-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C13H16N2 · HCl
CAS Number:
145108-58-3
Molecular Weight:
236.74
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dexmedetomidine hydrochloride, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +48 to +58°, c = 1 in H2O

storage condition

desiccated

color

white to beige

solubility

H2O: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

[Cl-].[N+H2]1C=NC=C1[C@@H](C)c2c(c(ccc2)C)C

InChI

1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1

InChI key

VPNGEIHDPSLNMU-MERQFXBCSA-N

Application

Dexmedetomidine hydrochloride has been used to study its effects on primary neonatal rat cardiomyocytes under hypoxic/reoxygenation conditions. It has also been used to study the effects of dexmedetomidine pretreatment on lipopolysaccharide-induced acute lung injury in mice.

Biochem/physiol Actions

Dexmedetomidine hydrochloride is a highly potent and selective α2-adrenergic agonist with analgesic and sedative properties, the (+)-isomer of medetomidine. Dexmedetomidine hydrochloride is used clinically as an anesthetic agent to reduce anxiety and tension and promote relaxation and sedation without causing respiratory depression.
Dexmedetomidine hydrochloride is a highly potent and selective α2-adrenergic agonist with analgesic and sedative properties.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Other Notes

2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research

Still not finding the right product?

Explore all of our products under Dexmedetomidine hydrochloride

pictograms

Exclamation markEnvironment
GHS07,GHS09

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - STOT SE 3

target_organs

Central nervous system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

DISCOVER Bioactive Small Molecules for Neuroscience

DISCOVER Bioactive Small Molecules for Neuroscience

신경과학을 위한 생체 활성 저분자

신경과학을 위한 생체 활성 저분자

Dexmedetomidine attenuates hypoxia/reoxygenation injury in primary neonatal rat cardiomyocytes
Ke Peng
Experimental and Therapeutic Medicine (2017)
Heedoo Yoo et al.
European journal of clinical pharmacology, 71(10), 1197-1207 (2015-08-04)
Dexmedetomidine is an α2-adrenoceptor agonist used for perioperative and intensive care sedation. This study develops mechanism-based population pharmacokinetic-pharmacodynamic models for the cardiovascular and central nervous system (CNS) effects of intravenously (IV) and intranasally (IN) administered dexmedetomidine in healthy subjects. Single
3-Methyladenine and dexmedetomidine reverse lipopolysaccharide-induced acute lung injury through the inhibition of inflammation and autophagy
Dengfeng Ding
Experimental and Therapeutic Medicine, 15.4 (2018)
View All Related Papers